Advocacy Resource
COVID-19 Resources for
the ALS Community
Below is a selection of pertinent information from ALS advocacy organizations regarding COVID-19 vaccines, as well as some general resources that may be helpful for the ALS community during the pandemic.
The links on this page are not affiliated with Mitsubishi Tanabe Pharma America, Inc. (MTPA). Links to sites outside of MTPA are provided as a resource to the viewer. MTPA accepts no responsibility for the content of linked sites.
-
COVID-19 Support Services including Vaccine InformationLes Turner Foundation
-
COVID-19 Vaccine FAQsMuscular Dystrophy Association
-
On-Demand Webinar: Caring for Oneself with ALS During COVID-19Muscular Dystrophy Association (sponsored in part by MTPA)
-
COVID-19: ALS TDI UpdatesALS Therapy Development Institute
If you want to learn more about COVID-19 facts, symptoms or how to get tested please visit the World Health Organization (WHO), Centers for Disease Control & Prevention (CDC) websites.
Registration of Clinical Trial Information and Disclosure of Results
a. Registration of our clinical trial information, and disclosure of results, to clinical trial registries
TPA will register and disclose information on publicly accessible clinical trial registries such as ClinicalTrials.gov regarding clinical trials that are being conducted or have been conducted.
b. Disclosure of clinical trial summary results
TPA will disclose the results from clinical trials in patients that form part of the submission package for products approved in the United States. Results will not be disclosed if TPA decides that disclosure may lead to identification of clinical trial participants. Results may not be disclosed under any of the following conditions:
- A third party, such as a company involved in joint development, has not agreed to disclosure.
- Disclosure may interfere with publication in medical journals.
- Disclosure may interfere with the protection of intellectual property rights.